
Daniel P Morin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7007239/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Wearable Cardioverter–Defibrillator after Myocardial Infarction. New England Journal of Medicine, 2018, 379, 1205-1215.	27.0	229
2	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2017, 19, 1556-1578.	1.7	186
3	The State of the Art. Mayo Clinic Proceedings, 2016, 91, 1778-1810.	3.0	154
4	Atrial Fibrillation in the 21st Century: A Current Understanding of Risk Factors and Primary Prevention Strategies. Mayo Clinic Proceedings, 2013, 88, 394-409.	3.0	125
5	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. Europace, 2018, 20, 1399-1421.	1.7	75
6	Predicting Persistent Left Ventricular Dysfunction FollowingÂMyocardial Infarction. Journal of the American College of Cardiology, 2016, 67, 1186-1196.	2.8	68
7	Relationships between the T-peak to T-end interval, ventricular tachyarrhythmia, and death in left ventricular systolic dysfunction. Europace, 2012, 14, 1172-1179.	1.7	61
8	Predictive Value of Microvolt T-Wave Alternans in Patients With Left Ventricular Dysfunction. Journal of the American College of Cardiology, 2007, 50, 166-173.	2.8	60
9	QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study. European Heart Journal, 2009, 30, 2908-2914.	2.2	59
10	T-peak to T-end interval for prediction of ventricular tachyarrhythmia and mortality in a primary prevention population with systolic cardiomyopathy. Heart Rhythm, 2015, 12, 1789-1797.	0.7	54
11	Impact of wearable cardioverterâ€defibrillator compliance on outcomes in the VEST trial: Asâ€treated and perâ€protocol analyses. Journal of Cardiovascular Electrophysiology, 2020, 31, 1009-1018.	1.7	52
12	Atrial Fibrillation and Heart Failure: Update 2015. Progress in Cardiovascular Diseases, 2015, 58, 126-135.	3.1	50
13	Lifestyle Modification in the Prevention and Treatment of Atrial Fibrillation. Progress in Cardiovascular Diseases, 2015, 58, 117-125.	3.1	47
14	Progression from Concentric Left Ventricular Hypertrophy and Normal Ejection Fraction to Left Ventricular Dysfunction. American Journal of Cardiology, 2011, 108, 992-996.	1.6	45
15	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. Journal of Arrhythmia, 2018, 34, 99-123.	1.2	41
16	Sudden cardiac death in Long QT syndrome (LQTS), Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT). Progress in Cardiovascular Diseases, 2019, 62, 227-234.	3.1	40
17	Usefulness of Precordial T-Wave Inversion to Distinguish Arrhythmogenic Right Ventricular Cardiomyopathy from Idiopathic Ventricular Tachycardia Arising from the Right Ventricular Outflow Tract. American Journal of Cardiology, 2010, 105, 1821-1824.	1.6	34
18	Optimal method of measuring the T-peak to T-end interval for risk stratification in primary prevention. Europace, 2018, 20, 698-705.	1.7	30

#	Article	IF	CITATIONS
19	Effect of bundle branch block on microvolt T-wave alternans and electrophysiologic testing in patients with ischemic cardiomyopathy. Heart Rhythm, 2007, 4, 904-912.	0.7	27
20	Prediction and Prevention of Sudden Cardiac Death. Cardiac Electrophysiology Clinics, 2017, 9, 631-638.	1.7	26
21	The impact of revascularization on myocardial blood flow as assessed by positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1226-1239.	6.4	26
22	Cardiac resynchronization therapy: history, present status, and future directions. Ochsner Journal, 2014, 14, 596-607.	1.1	26
23	Surface Electrocardiogram Predictors of Sudden Cardiac Arrest. Ochsner Journal, 2016, 16, 280-9.	1.1	26
24	Effect of oral β-blocker therapy on microvolt T-wave alternans and electrophysiology testing in patients with ischemic cardiomyopathy. American Heart Journal, 2007, 153, 392-397.	2.7	21
25	Cancer Radiation Therapy May Be Associated With Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 2021, 8, 610915.	2.4	21
26	Atrial Fibrillation and Congestive Heart Failure. Heart Failure Clinics, 2014, 10, 305-318.	2.1	19
27	Tailored activated carbons for supercapacitors derived from hydrothermally carbonized sugars by chemical activation. RSC Advances, 2016, 6, 110629-110641.	3.6	17
28	The effect of coronary revascularization on regional myocardial blood flow as assessed by stress positron emission tomography. Journal of Nuclear Cardiology, 2017, 24, 961-974.	2.1	16
29	Cardiometabolic Risk Factors and Atrial Fibrillation. Reviews in Cardiovascular Medicine, 2013, 14, 73-81.	1.4	16
30	Current Evidence-Based Understanding of the Epidemiology, Prevention, and Treatment of Atrial Fibrillation. Current Problems in Cardiology, 2018, 43, 241-283.	2.4	14
31	Effects of hydrothermal carbonization conditions on the textural and electrical properties of activated carbons. Carbon, 2016, 107, 619-621.	10.3	13
32	Sudden cardiac death in nonischemic cardiomyopathy. Progress in Cardiovascular Diseases, 2019, 62, 235-241.	3.1	13
33	Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease. Journal of Cardiovascular Electrophysiology, 2020, 31, 607-611.	1.7	13
34	Cardiometabolic risk factors and atrial fibrillation. Reviews in Cardiovascular Medicine, 2013, 14, e73-81.	1.4	12
35	Computed tomography of a coronary sinus diverticulum associated with Wolff-Parkinson-White syndrome. Heart Rhythm, 2012, 9, 1338-1339.	0.7	9
36	Leadless and Wireless Cardiac Devices: The Next Frontier in Remote Patient Monitoring. Current Problems in Cardiology, 2021, 46, 100800.	2.4	7

#	Article	IF	CITATIONS
37	Management of Perioperative Anticoagulation for Device Implantation. Cardiac Electrophysiology Clinics, 2018, 10, 99-109.	1.7	6
38	Cost-Saving Opportunities with Appropriate Utilization of Cardiac Telemetry. American Journal of Cardiology, 2018, 122, 1570-1573.	1.6	6
39	Epidemiology, evaluation, and management of conduction disturbances after transcatheter aortic valve replacement. Progress in Cardiovascular Diseases, 2021, 66, 37-45.	3.1	6
40	Advances in the Prevention and Treatment of Atrial Fibrillation. Progress in Cardiovascular Diseases, 2015, 58, 103-104.	3.1	5
41	Non-arrhythmic causes of sudden death: A comprehensive review. Progress in Cardiovascular Diseases, 2019, 62, 265-271.	3.1	5
42	Direct His bundle pacing using retrograde mapping in complete heart block and L-transposition of the great arteries. HeartRhythm Case Reports, 2019, 5, 291-293.	0.4	5
43	Impact of Preinfection Left Ventricular Ejection Fraction on Outcomes in COVID-19 Infection. Current Problems in Cardiology, 2021, 46, 100845.	2.4	5
44	An Uncommon Cause of Pacemakerâ€Mediated Ventricular Tachycardia. Journal of Cardiovascular Electrophysiology, 2014, 25, 107-109.	1.7	4
45	Natural History and Implantable Cardioverter-Defibrillator Implantation After Revascularization for Stable Coronary Artery Disease With Depressed Ejection Fraction. Clinical Cardiology, 2015, 38, 715-719.	1.8	4
46	The ENHANCE-AF clinical trial to evaluate an atrial fibrillation shared decision-making pathway: Rationale and study design. American Heart Journal, 2022, 247, 68-75.	2.7	4
47	Selective Estrogen-Receptor Modulators. New England Journal of Medicine, 2003, 348, 2259-2259.	27.0	3
48	Advances in the Risk Stratification, Prevention, and Treatment of Sudden Cardiac Death. Progress in Cardiovascular Diseases, 2019, 62, 203-204.	3.1	3
49	The wearable cardioverter-defibrillator vest: Indications and ongoing questions. Progress in Cardiovascular Diseases, 2019, 62, 256-264.	3.1	3
50	Management of ventricular tachycardia in the absence of structural heart disease. Current Treatment Options in Cardiovascular Medicine, 2007, 9, 356-363.	0.9	2
51	latrogenic Twiddler's Syndrome. Journal of Interventional Cardiac Electrophysiology, 2010, 29, 135-137.	1.3	2
52	Bitumen Shear Mechanics in a Dynamic Subsea Electrical Cable. , 2015, , .		2
53	Editorial commentary: MADIT–CRT and his many sons. Trends in Cardiovascular Medicine, 2016, 26, 147-149.	4.9	2
54	Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. Progress in Cardiovascular Diseases, 2021, 66, 53-60.	3.1	2

#	Article	IF	CITATIONS
55	Blood Thinners for Atrial Fibrillation Stroke Prevention. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009389.	4.8	2
56	Development and validation of a multivariable risk prediction model for COVID-19 mortality in the Southern United States. Mayo Clinic Proceedings, 2021, 96, 3030-3041.	3.0	2
57	The Many Faces of Sudden Death. Mayo Clinic Proceedings, 2016, 91, 1489-1492.	3.0	1
58	First in human: the effects of biventricular pacing on cardiac output in severe pulmonary arterial hypertension. Heart and Vessels, 2020, 35, 852-858.	1.2	1
59	In reply: Impaired myocardial blood flow in atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2020, 31, 1883-1883.	1.7	1
60	Google Search Activity and Heart Failure: Analysis of the US Population's Interest in Heart Failure and Its Correlation with Heart Failure-Associated Mortality. Journal of Cardiac Failure, 2021, 27, 123-125.	1.7	1
61	The role of atrial fibrillation catheter ablation in patients with heart failure. Progress in Cardiovascular Diseases, 2021, 66, 80-85.	3.1	1
62	Critical role of cardiac magnetic resonance in the diagnosis of left-dominant arrhythmogenic cardiomyopathy: A paradigmatic case in a recreational middle-aged athlete. HeartRhythm Case Reports, 2021, 7, 453-456.	0.4	1
63	Implantable Cardioverter-defibrillators in Adult Congenital Heart Disease. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3172-3181.	0.5	1
64	Quantification of Resting Myocardial Blood Flow Using Rubidium ⁸² Positron Emission Tomography in Regions with MRI-Confirmed Myocardial Scar. Annals of Nuclear Cardiology, 2022, 8, 7-13.	0.2	1
65	Is the Match Illegal?. New England Journal of Medicine, 2003, 348, 2259-2262.	27.0	0
66	Reply to Madias et al. Is the Different Frequency of T-Wave Inversion in Arrhythmogenic Right Ventricular Cardiomyopathy and Idiopathic Ventricular Tachycardia Due to Different Frequency and Duration of Ventricular Ectopy Inducing a Different Degree of Cardiac Memory Effect? Am J Cardiol 2010;106:1522. American Journal of Cardiology, 2011, 107, 144.	1.6	0
67	Laser-assisted extraction of a pacing lead with a supraclavicular course. HeartRhythm Case Reports, 2015, 1, 120-122.	0.4	0
68	Evaluating the benefits of home-based management of atrial fibrillation: current perspectives. Journal of Pragmatic and Observational Research, 2016, Volume 7, 41-53.	1.5	0
69	In Reply—Atrial Fibrillation: Interatrial Block May Be an Underdiagnosed and Easily Recognizable Risk Factor. Mayo Clinic Proceedings, 2017, 92, 682.	3.0	0
70	Extreme "cannon A waves―and pulsatile skin color in complete heart block. HeartRhythm Case Reports, 2017, 3, 493.	0.4	0
71	To the Editor— Disseminated intravascular coagulation as a cause of shock related to device extraction. Heart Rhythm, 2018, 15, e35.	0.7	0
72	Pacemaker failure as a cause of sudden death. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 293-293.	2.8	0

#	Article	IF	CITATIONS
73	Editorial commentary: Arrhythmias in patients with left ventricular assist devices: Pump fixed; rhythm … not so much. Trends in Cardiovascular Medicine, 2018, 28, 51-52.	4.9	0
74	HRS publications' online development. Heart Rhythm, 2018, 15, 797.	0.7	0
75	Who Should Receive a Wearable Defibrillator Vest at Hospital Discharge?. Current Cardiology Reports, 2019, 21, 125.	2.9	0
76	In reply—Atrial Fibrillation and Morbidity and Mortality in Stress-Induced Cardiomyopathy. Mayo Clinic Proceedings, 2019, 94, 2148-2149.	3.0	0
77	Editorial commentary: The Checklist Manifesto: Cardiogenic Shock Edition. Trends in Cardiovascular Medicine, 2019, 29, 418-419.	4.9	0
78	Utility of serial measurement of biomarkers of cardiovascular stress and inflammation in systolic dysfunction. Europace, 2020, 22, 1044-1053.	1.7	0
79	Positron emission tomography absolute stress myocardial blood flow for risk stratification in nonischemic cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2020, 31, 1137-1146.	1.7	Ο
80	PET Stress Testing with Coronary Flow Capacity in the Evaluation of Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Rethinking the Current Paradigm. Current Cardiology Reports, 2021, 23, 50.	2.9	0
81	Diagnosis of pulmonary embolism: Know your strengths well, and know your weaknesses better. Trends in Cardiovascular Medicine, 2021, , .	4.9	0
82	A little Red Bull may give you wings, but it probably will not affect your Tpe. Anatolian Journal of Cardiology, 2015, 15, 923-924.	0.9	0
83	From the Editor's Desk: Ochsner Journal Focus Issue: Cardiovascular Diseases. Ochsner Journal, 2016, 16, 193.	1.1	0
84	Correction to "Cardiometabolic Risk Factors and Atrial Fibrillation―[Rev Cardiovasc Med. 2013;14(2-4):e73-e81]. Reviews in Cardiovascular Medicine, 2014, 15, 74-74.	1.4	0